Latest Conference Coverage

Al-Zaidy, the vice president of clinical development and lead on the GM1 Program at Passage Bio, discussed the results of the phase 1/2 Imagine-01 clinical trial of PBGM01.

Long term data from 2 clinical trials and expanded access programs were presented at WORLDSymposium 2023.

The patient has not re-started any of his previous Gaucher-specific therapy since receiving AVR-RD-02.

Two patients treated with AVR-RD-02 showed clinically meaningful reductions in liver size.

FBX-101 showed promising efficacy and has been well-tolerated so far in the RESKUE trial.

The assistant professor of medicine and pediatrics at Stanford University discussed updated data from 2 studies of Orca-T cell therapy.

The professor medicine and pediatrics at Washington University in St. Louis overviewed data from the SPEARHEAD-1 trial of afami-cel.

By 3 months, 12 of 17 patients treated with a full cycle of EG-70 achieved a complete response.

The assistant professor of medicine at Vanderbilt University Medical Center discussed results from a retrospective analysis presented at the 2023 Tandem Meetings.

The assistant professor of medicine, bone marrow transplantation and cellular therapy, Stanford, discussed favorable data from a real-world experience study.

The hematologist/oncologist at Cincinnati Children’s discussed unfavorable outcomes with tisa-cel reinfusion in patients with B-cell acute lymphocytic leukemia.

Median PFS was 13.3 months in the ide-cel arm, compared to 4.4 months for the SOC arm.

The locum consultant of pediatric BMT and leukemia at Royal Manchester Children’s Hospital discussed the limited distribution model of arsa-cel in Europe.

Patients with large B-cell lymphoma had an ORR of 68% and a CR rate of 53%.

No adverse events related to RP-L201 have been reported to date.

Among the 14 patients with relapsed/refractory mantle cell lymphoma who were treated with LV20.19 CAR in the trial, the overall response at 28 days post-treatment was 100%.

The associate professor of medicine at Medical College of Wisconsin discussed trials assessing the dual, CD19/CD20-targeting CAR T therapy.

Neither patient treated with RP-L301 required RBC transfusions at any point post-engraftment.

The associate professor of medicine from University of Pennsylvania discussed advantages of huCART19-IL18 in NHL and CLL.

The associate attending physician at Memorial Sloan Kettering Cancer Center discussed further research that remains to be conducted with the allogeneic cell therapy.

The assistant member of the department of malignant hematology at Moffitt Cancer Center discussed updated data on the allogeneic CAR T therapy, UNICART123v1.2.

The professor at University Hospital Dresden discussed the positive safety profile of Unicar-T-CD123.

Simeone discussed the progress and challenges seen so far in the BASECAMP-1 observational study.

Simeone discussed the design of BASECAMP-1, an observational study for patients previously treated for solid tumors who are at a high risk of relapse.

Steven Pipe, MD, CS Mott Children’s Hospital, discussed the latest follow-up data from the HOPE-B study of the approved therapy, Hemgenix.

The assistant member of the bone marrow transplant department at St. Jude Children’s Research Hospital discussed advantages of OTQ923 in treating SCD.

The associate professor of medicine at Siteman Cancer Center and WUSTL discussed further research to be done with CAR T-cell therapies.

Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, Co-Founder, Executive Vice President, and Chief Medical Officer, CLL Society, discussed the role the society plays in the field.